Our offer for your IHC on glioma tissue: Get your individual discount when odering your anti-IDH1 R132H antibody DIA-H09 together with ATRX or H3 K27M from dianova*
IDH1 R132H
IDH1 R132H immunohistochemistry forms a backbone for the differential diagnosis of gliomas. Anti-IDH1 R132H clone H09 (DIA-H09) is an indispensable tool for Glioma diagnosis with high impact on cancer research as documented by nearly 100 scientific publications on CiteAb.
ATRX
ATRX mutations in gliomas result in the loss of nuclear ATRX expression, which can be diagnosed by IHC analysis. Loss of ATRX expression is close to being mutually exclusive to 1p/19q co-deletion. dianova’s antibody clone AX1 was developed specially for the detection of ATRX in glioma tissue.
H3 K27M
The WHO classification 2016 describes the diffuse midline glioma with H3-K27M mutation as a new entity. It is most common in children and adolescents and is localized in midline structures. The clone RM192 enables clear detection of somatic H3 K27M mutations in glioma tissue.
The WHO-classification for CNS Tumors 2016 recommends the analysis of new molecular markers on formalin-fixed tissues together with classical histomorphology. The focus here is on immunohistochemical determination of the IDH1, ATRX and H3-K27M mutation status. Successive integration of IHC procedures reduces the number of molecular tests required for unequivocal diagnosis (Reus et al., 2015).
* Please forward your quotation request to info@dianova.de
